ARMP
Armata Pharmaceuticals Inc
3.70$
+4.0%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 1995 | 1996 | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| -1,400.0% | -82.6% | -177.8% | -22.2% | -23.5% | -15.6% | 199.2% | 153.9% | 122.2% | 179.1% | 264.8% | 146.8% | 171.4% | 174.2% | 100.0% | – | – | 25.2% | – | – | 141.9% | 325.2% | – | 4,358.1% | 1,755.0% | 447.4% | 635.7% | 21.5% | 665.4% | 31.2% | |
| 1,500.0% | 182.6% | 277.8% | 122.2% | 123.5% | 115.6% | 100.0% | -53.9% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | – | – | 100.0% | 74.8% | 100.0% | 100.0% | -41.9% | -225.2% | – | -4,358.1% | -1,655.0% | -347.4% | -535.7% | 78.5% | -565.4% | 68.8% | |
| 8,200.0% | 500.0% | 1,444.4% | 184.7% | 210.3% | 169.4% | 167.1% | 152.0% | 122.2% | 179.1% | 264.8% | 146.8% | 171.4% | 174.2% | – | 591.7% | 222.9% | 2,000.6% | 1,419.3% | 840.4% | 2,183.8% | 2,505.2% | – | 31,690.3% | 1,755.0% | 447.4% | 635.7% | 745.6% | 665.4% | 483.6% | |
| 2,300.0% | 126.1% | 311.1% | 41.7% | 52.9% | 50.1% | 32.9% | 41,726,581.5% | 39.0% | 68.9% | 91.8% | 64.7% | 68.0% | 66.8% | – | 2,775.0% | 483.1% | 1,844.9% | 1,674.8% | 1,412.6% | 3,235.8% | 6,600.0% | – | 29,887.1% | 967.9% | 185.1% | 135.0% | 257.2% | 254.8% | 253.0% | |
| 11,900.0% | 708.7% | 1,933.3% | 248.6% | 286.8% | 249.8% | 32.9% | 41.3% | 39.0% | 68.9% | 91.8% | 452.0% | 68.0% | 240.9% | 86.1% | 3,358.3% | 706.0% | 3,835.4% | 3,549.9% | 2,253.1% | 9,091.5% | 14,148.7% | – | 57,219.4% | 967.9% | 185.1% | 135.0% | 981.4% | 254.8% | 705.4% | |
| -10,400.0% | -526.1% | -1,655.6% | -126.4% | -163.2% | -401.7% | -151.5% | -95.2% | -98.1% | -157.2% | -281.5% | -372.4% | -160.2% | -242.8% | 13.9% | -3,258.3% | -606.0% | -4,611.1% | -3,449.9% | -2,153.1% | -8,991.5% | -14,048.7% | – | -61,577.4% | -2,623.0% | -532.5% | -670.8% | -902.8% | -820.2% | -636.7% | |
| 300.0% | 17.4% | 0.0% | 4.2% | 0.0% | 2.3% | 2.4% | 7.4% | 8.6% | 4.9% | 7.4% | 4.2% | 0.0% | 0.0% | – | 108.3% | 51.1% | 880.9% | 0.0% | 0.0% | 0.0% | 0.0% | – | 3,003.2% | 76.3% | 1.4% | 0.5% | 58.0% | 207.6% | 338.3% | |
| -9,900.0% | -1,130.4% | -1,577.8% | -120.8% | -392.6% | -417.9% | -143.9% | -113.0% | -105.4% | -147.7% | -279.3% | -344.6% | -156.1% | -237.7% | 65.3% | -3,158.3% | -641.6% | -17,972.6% | 5,650.1% | -124.0% | -7,459.2% | -12,295.7% | – | -62,835.5% | -2,695.1% | -517.5% | -670.2% | -1,524.5% | -365.6% | -3,544.0% | |
| 9,900.0% | 1,130.4% | 1,577.8% | 120.8% | 392.6% | 417.9% | 143.9% | 122.9% | 105.4% | 147.7% | 279.3% | 344.6% | 156.1% | 237.7% | – | – | -474.4% | 13,361.5% | -9,100.0% | -15.4% | -213.8% | -1,132.2% | – | -1,464.5% | 77.0% | 1.4% | -0.5% | – | – | – | |
| -9,900.0% | -1,130.4% | -1,577.8% | -120.8% | -392.6% | -417.9% | -143.9% | -122.9% | -105.4% | -147.7% | -279.3% | -344.6% | -156.1% | -237.7% | 65.3% | -3,158.3% | -167.2% | -19,871.7% | 5,650.1% | -108.6% | -7,245.4% | -11,163.5% | – | -62,835.5% | -2,695.1% | -517.5% | -670.2% | -1,524.5% | -365.6% | -3,544.0% | |
| -9,000.0% | -443.5% | -1,477.8% | -104.2% | -139.7% | -371.3% | -105.5% | -76.9% | -44.0% | -134.7% | -237.4% | -333.1% | -133.6% | -135.0% | 65.3% | -3,200.0% | -581.5% | -18,954.2% | -2,955.5% | -2,153.1% | -5,177.7% | -8,680.0% | – | -55,474.2% | -2,483.5% | -490.0% | -653.5% | -1,445.1% | -132.4% | -3,174.5% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.